Dermokine CRISPR/Cas9 KO Plasmid (h): sc-406705
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Dermokine CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Dermokine genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Dermokine CRISPR/Cas9 KO Plasmid (h) | sc-406705 | 20 µg | $397.00 |
Overview
DMKN encodes dermokine, a secreted protein predominantly expressed in stratified epithelia, where it contributes to epidermal differentiation, barrier maintenance, and tissue homeostasis. Dermokine is associated with keratinocyte maturation programs and extracellular signaling that can influence inflammatory cues and epithelial–stromal interactions. Altered DMKN expression has been reported in skin disorders and in epithelial cancers, supporting its relevance to studies of barrier dysfunction, dysregulated differentiation, and tumor-associated microenvironmental remodeling. As a skin-enriched factor, DMKN is frequently examined in transcriptomic and proteomic workflows linking epithelial state transitions to disease-associated signaling.
Dermokine CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the DMKN gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the DMKN together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the DMKN open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Dermokine protein expression.
This CRISPR knockout system enables efficient generation of DMKN-deficient cell models for investigation of Dermokine signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting DMKN exon(s) critical for Dermokine function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple DMKN genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Dermokine CRISPR/Cas9 KO Plasmid (h) and Dermokine CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the DMKN locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Dermokine HDR Plasmid (h) and Dermokine HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by DMKN homology arms to support homology-directed repair at defined DMKN target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.